Omeros | OMER

Peers Price Chg Day Year Date
Adma Biologics 16.41 -0.46 -2.73% -10.72% Sep/08
Alnylam Pharmaceuticals 455.03 3.03 0.67% 79.74% Sep/08
BioMarin Pharmaceutical 56.38 -1.39 -2.41% -33.14% Sep/08
Cytokinetics 52.06 -0.95 -1.79% -6.75% Sep/08
Dynavax Technologies 9.70 -0.36 -3.58% -10.76% Sep/08
Gilead Sciences 115.88 0.83 0.72% 46.41% Sep/08
Knight Therapeutics 6.45 0.01 0.16% 14.56% Sep/08
Insmed 146.68 1.58 1.09% 104.23% Sep/08
MacroGenics 1.76 -0.24 -12.00% -48.99% Sep/08
Pacira 26.74 0.29 1.10% 102.12% Sep/08
Pfizer 24.55 -0.33 -1.33% -16.50% Sep/08
Sarepta Therapeutics 17.60 -1.11 -5.93% -86.22% Sep/08
United Therapeutics 394.62 -5.90 -1.47% 13.17% Sep/08
Vertex Pharmaceuticals 395.25 -0.87 -0.22% -16.04% Sep/08

Indexes Price Day Year Date
USND 21799 98.31 0.45% 29.10% Sep/08
US2000 2396 5.00 0.21% 14.22% Sep/08

Omeros traded at $3.43 this Tuesday April 9th, increasing $0.01 or 0.29 percent since the previous trading session. Looking back, over the last four weeks, Omeros gained 18.33 percent. Over the last 12 months, its price fell by 33.27 percent. Looking ahead, we forecast Omeros to be priced at 3.40 by the end of this quarter and at 3.32 in one year, according to Trading Economics global macro models projections and analysts expectations.

Omeros Corporation is a commercial-stage biopharmaceutical company. The Company is engaged in discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, complement-mediated diseases, disorders of the central nervous system and immune-related diseases, including cancers. Its lead drug product OMIDRIA (phenylephrine and ketorolac intraocular solution) is used during cataract surgery or intraocular lens replacement for adult and pediatric patients. Its drug candidate narsoplimab is the subject of a biologics license application (BLA) for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA). It also has multiple Phase III and Phase II clinical-stage development programs in its pipeline, which are focused on complement-mediated disorders, including immunoglobulin A (IgA) nephropathy, atypical hemolytic uremic syndrome (aHUS) and COVID-19.